Safety of COVID-19 vaccination in patients with mastocytosis and monoclonal mast cell activation syndrome
21st March 2025
Rayan Kaakati, Dilawar Khokhar, Cem Akin (2021). This is a retrospective study about the safety of COVID vaccine in patients with different forms of mastocytosis and a history of anaphylaxis. The study highlights that a history of anaphylaxis should not exclude people from vaccination but precautions should be taken to limit the risks (continue current medication, premedication with antihistamine and access to Epipen if normally carried)
Become a friend
Sign up to become a Friend of Mast Cell Action so we can keep you up to date on our progress and on how to get involved in our latest campaigns and initiatives.
Donate
Mast Cell Action relies entirely on the generosity of people like you. Please make a donation now and together we can make a difference to those affected by MCAS.
